Do you have questions men's health related?
Please send them!
If you have a question related to men's health, please fill the form bellow.
1. It is a must to provide a valid email, unless you want your questions to be ignored.
We won't make your email public, but we like to talk with live persons.
2. To protect
your identity, take care the name you fill. We make public your name exactly as it is.
|
Public release date: 14 December 2007
[
]
More evidence suggests diabetes drug may be dangerous
A popular class of drugs for treating type 2 diabetes is under scrutiny
again. A new Canadian study released by the Institute for Clinical
Evaluative Sciences (ICES) finds that drugs such as Avandia increase the
risk of heart failure, heart attacks and death.
Published in the December 12th issue of JAMA, ICES scientists looked at the
glitazone class of drugs including rosiglitazone (Avandia) and pioglitazone
(Actos) in the first real world population-based study of its kind. All
Ontario residents aged 65 years or older, treated with at least one oral
diabetic medication were followed between 2002 and 2006.
"The necessity for evaluating diabetes drug outcomes in older patients is
reinforced by the fact that seniors have the highest prevalence of diabetes
and represent over 40% of the population with the disease," says lead author
and ICES researcher, Dr. Lorraine Lipscombe. "We cannot be certain whether
similar effects would be seen in younger patients. Our study represents a
concern for older patients taking these drugs who are at higher risk for
adverse cardiac outcomes."
The ICES study explored three distinct outcomes using Ontario health care
databases: hospital visits for congestive heart failure, hospital visits for
heart attacks and death from any cause, and looked at exposure to specific
diabetes drugs in seniors. Compared to other diabetes pills glitazones
(Avandia & Actos ) are associated with the following results:
- 60% relative increase in heart failure, 40% relative increase in heart
attacks, 30% relative increase in death.
- This translates into an estimated 3 additional episodes of heart
failure, 4 additional heart-attacks and 5 additional deaths for every 100
individuals taking these drugs, over a 4 year period in a high-risk older
population.
- Risk predominantly among those taking rosiglitazone (Avandia).
- Smaller numbers of people received the other drug pioglitazone (Actos),
limiting our ability to be certain about adverse events in this group.
|
|
